AdventHealth Translational Research Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, AdventHealth Translational Research Institute sits in the top decile of US sponsors by registered trial count (#351 of 15,742 sponsors by registered trial count).
AdventHealth Translational Research Institute: 54 sponsored US clinical trials, 13 recruiting.
AdventHealth Translational Research Institute sponsors 54 registered US clinical trials on ClinicalTrials.gov, 13 of them currently recruiting, and 17 completed. 0 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 7 trials.
Top-decile sponsor footprint
AdventHealth Translational Research Institute ranks in the top decile of sponsors by registered trial count (#351 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
17 of 19 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
54 total, page 1 of 2
Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of Hepatic Steatosis
NCT06993454
Assessments of Adipogenesis, Lipid Turnover and Cellular Composition in Adipose Tissue in Response to Endurance Exercise
NCT06602141
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
NCT06008977
Accessing Care, Clinical Trials and Screening for Underserved Children and Adults With Type 1 Diabetes (ACCESS-T1D)
NCT06908057
ImpaCt Of Shiftwork on METabolic Flexibility and Skeletal Muscle Clocks
NCT05820490
Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer
NCT05773144
Effects of Aerobic Exercise on Skeletal Muscle Remodeling in Colorectal Cancer
NCT05789433
AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
NCT04807868
Dynamic in Vivo PET Imaging and ex Vivo Biopsies From Skeletal Muscle and Adipose Tissue to Investigate the Effects of Exercise on Insulin Resistance and Mitochondrial Energetics in Type 2 Diabetes
NCT04754581
Investigating the Effects of Aerobic and Resistance Training in Vivo on Skeletal Muscle Metabolism in Vitro in Primary Human Muscle Cells (MoTrMyo)
NCT04334343
The Role of Type 2 Diabetes on Skeletal Muscle Atrophy and Recovery Following Bed Rest in Older Adults
NCT03761446
Magnetic Resonance & Optical Spectroscopy Validation
NCT01827527
Development and Validation of Multi-nuclear Magnetic Resonance Imaging and Spectroscopy for Whole Body Human Applications
NCT02663362
Spatiotemporal Dimensions of Metabolism in Autochthonous Tumors of GBM Patients
NCT06054529
Low-CArbohydrate Diet and SGLT2-INhibitOr to Achieve Moderate Ketosis in Healthy Volunteers
NCT05662865
Davos Alzheimer's Collaborative Study: Sequential Administration of Digital Testing To Screen For Cognitive Impairment Followed By Blood Based Biomarkers To Assist With Timely Detection And Accurate Diagnosis Of Alzheimer's Disease
NCT05379348
Microbiome-Mediated Gut Dysfunction in Non-Alcoholic Fatty Liver Disease
NCT05209100
REsearching Covid-19 Outcomes in Diabetes (RECODE)
NCT04805970
Effects of MetAP2 Inhibition on Bioenergetics and Aging-associated Characteristics in Adipose Tissue in Healthy Participants
NCT05989035
Transcriptional and Epigenetic Program of PCOS Women
NCT04034706
Development of Novel Biomarkers for the Early Diagnosis of Type 1 Diabetes
NCT04164966
CharacterIzation of Adult Onset Autoimmune Diabetes
NCT03971955
Electrical Stimulation of Human Myocytes in Microgravity
NCT03665051
Brown Adipose Tissue Pilot
NCT03793127
Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects
NCT03139305
Identifying Targets of Maladaptive Metabolic Responses in Heart Failure
NCT03032627
To Determine Tolerability to Glucagon Infusion in Obese Subjects
NCT02817659
Epigenetic Regulation of Human Adipose Tissue Distribution
NCT02728635
Collection of Human Tissue Samples From the Neck Region for Characterization of Its Molecular and Biochemical Signatures
NCT02274805
Muscle Insulin Resistance in Aging (Mirage)
NCT02230839
Exercise Resistance in Type 2 Diabetes
NCT01911104
Identification of Novel Skeletal Muscle-derived Factors That Promote Lipid Oxidation (Columbus)
NCT01911091
Adipose Tissue and Polycystic Ovary Syndrome (PCOS)(EIFFEL)
NCT01745471
Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT-2 Inhibitors
NCT07421518
Determining Cell- and Spatially-distinct Skeletal Muscle Transcriptional Aberrations in Insulin Resistance
NCT07516509
Measurement of NAD+ Synthesis in Human Skeletal Muscle
NCT04905446
GPR119 Agonist for Hypoglycemia in Type 1 Diabetes
NCT04432090
Abscisic Acid Effects on Glucose Homeostasis and Insulin Sensitivity
NCT04722354
Brown Adipose Tissue as a Therapeutic for the Metabolic and Cardiac Dysfunction With Senescence (BATSR)
NCT04168580
Exercise Training as an Intervention to Improve Muscle Function and Recovery Following Bed Rest in Older Adults With Type 2 Diabetes
NCT04057677
The Role of Microbiome Reprogramming on Liver Fat Accumulation
NCT03914495
Biomarkers of Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis Following Bariatric Surgery
NCT03294850
The Influence of Glycemic Control and Obesity on Energy Balance and Metabolic Flexibility in Type 1 Diabetes
NCT03379792
Effect of Nesiritide Infusion on Insulin Sensitivity in Healthy Obese Insulin Resistant Subjects
NCT03234751
Integrating Quantitative Energetics Determines the Microbiome's Contribution to Energy Balance
NCT02939703
Interactions of Human Gut Microbiota With Intestinal Sweet Taste Receptors
NCT03032640
Collection of Gastrointestinal Tissue Samples for the Characterization and ex Vivo Functional Assessment of Chemoreceptors
NCT02859116
Effect of AT-derived miRNA on the Biology and Insulin Sensitivity of Skeletal Muscle in Humans
NCT02459106
Effects of Glucagon Administration on Energy Expenditure
NCT02237053
Intestinal Sweet Taste Receptor Function and Adaptation to Dietary Sugars and Sweeteners
NCT02835859
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 3 |
Therapeutic Areas
What is open in the AdventHealth Translational Research Institute pipeline
13 recruiting of 54 indexed (24% open); 17 completed (31%).
Phase mix: 0 late (III/IV) vs 9 early (I/II) (early-phase heavy).
Top condition: Obesity (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
AdventHealth Translational Research Institute: open-pipeline peers nationwide
Peers matched on 54 registered trials and 24% open enrollment, not the therapeutic-area sidebar.
AdventHealth Translational Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 54 trials (± recruiting share)
- Auburn University · 54 trials · 24% recruiting
- Brooke Army Medical Center · 54 trials · 11% recruiting
- Corcept Therapeutics · 54 trials · 11% recruiting
- Pharmacyclics · 54 trials · 0% recruiting
Sponsors near 24% open enrollment (± trial volume)
- Center for International Blood and Marrow Transplant Research · 24% recruiting · 29 trials
- Boston Children's Hospital · 24% recruiting · 462 trials
- Genmab · 24% recruiting · 45 trials
- Chugai Pharmaceutical · 24% recruiting · 17 trials
Related
What to do with this AdventHealth Translational Research Institute page
54 registered trials is a research-attention snapshot, not an endorsement of AdventHealth Translational Research Institute or any single study.
- 13 of AdventHealth Translational Research Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition AdventHealth Translational Research Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
AdventHealth Translational Research Institute pipeline card: 54 registered trials from official public datasets.Report a data error.